Literature DB >> 22314424

Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma.

Florie Borel1, Pavlina Konstantinova, Peter L M Jansen.   

Abstract

MicroRNAs (miRNAs) are evolutionary conserved small non-coding RNAs that regulate gene expression by mediating post-transcriptional silencing of target genes. Since miRNAs are involved in fine-tuning of physiological responses, they have become of interest for diagnosis and therapy of a number of diseases. Moreover, the role of dysregulated miRNAs in maintaining the malignant phenotype has profound implications for cancer therapy. We will review the best defined cellular miRNAs and changes in their expression profile in hepatocellular carcinoma (HCC). Cellular miRNAs can also be released into the circulation, and these miRNAs are detected in most body fluids. Circulating miRNAs are associated with HCC and are possible biomarkers. Finally, by affecting several clinically relevant targets, artificially increasing or decreasing the expression level of a given miRNA offers fascinating therapeutic perspectives. We will therefore highlight recent developments in miRNA-based gene therapy with a focus on their therapeutic potential for HCC.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22314424     DOI: 10.1016/j.jhep.2011.11.026

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  107 in total

Review 1.  Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications.

Authors:  Chun-Ming Wong; Felice Ho-Ching Tsang; Irene Oi-Lin Ng
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-01-10       Impact factor: 46.802

Review 2.  microRNA: a promising diagnostic biomarker and therapeutic target for hepatocellular carcinoma.

Authors:  Xiaofei Li; Wenjun Yang; Lianqing Lou; Yongxin Chen; Shuang Wu; Guoqiang Ding
Journal:  Dig Dis Sci       Date:  2014-01-04       Impact factor: 3.199

3.  MicroRNA-145 and MicroRNA-133a Inhibited Proliferation, Migration, and Invasion, While Promoted Apoptosis in Hepatocellular Carcinoma Cells Via Targeting FSCN1.

Authors:  Guohui Wang; Shaihong Zhu; Yonghong Gu; Qian Chen; Xinrong Liu; Hua Fu
Journal:  Dig Dis Sci       Date:  2015-07-15       Impact factor: 3.199

4.  Exploration of genome-wide circulating microRNA in hepatocellular carcinoma: MiR-483-5p as a potential biomarker.

Authors:  Jing Shen; Antai Wang; Qiao Wang; Irina Gurvich; Abby B Siegel; Helen Remotti; Regina M Santella
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-10-14       Impact factor: 4.254

Review 5.  MicroRNA: a connecting road between apoptosis and cholesterol metabolism.

Authors:  Yogita K Adlakha; Neeru Saini
Journal:  Tumour Biol       Date:  2016-04-22

Review 6.  Noncoding RNA as therapeutic targets for hepatocellular carcinoma.

Authors:  Joseph George; Tushar Patel
Journal:  Semin Liver Dis       Date:  2015-01-29       Impact factor: 6.115

7.  New evidence of lncRNA role in tumor progression and metastasis.

Authors:  Jae Hong Im; Ruth J Muschel
Journal:  Hepatobiliary Surg Nutr       Date:  2012-12       Impact factor: 7.293

8.  Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma.

Authors:  Giacomo Diaz; Marta Melis; Ashley Tice; David E Kleiner; Lopa Mishra; Fausto Zamboni; Patrizia Farci
Journal:  Int J Cancer       Date:  2013-03-16       Impact factor: 7.396

9.  Increased expression of long intergenic non-coding RNA LINC00152 in gastric cancer and its clinical significance.

Authors:  Qianqian Pang; Jiaxin Ge; Yongfu Shao; Weiliang Sun; Haojun Song; Tian Xia; Bingxiu Xiao; Junming Guo
Journal:  Tumour Biol       Date:  2014-02-13

10.  Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma.

Authors:  J Qi; J Wang; H Katayama; S Sen; S M Liu
Journal:  Neoplasma       Date:  2013       Impact factor: 2.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.